$2.28
0.2110.14%
Last update: Nov 9, 4:01 PM
Niagen Bioscience Inc
NAGENASDAQ
Niagen Bioscience fell 67.9% from $7.10 to $2.28, behind the S&P 500's +10.5%. Its worst day was Nov 5 (−16.5%), and its low came Nov 6 at $2.07.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Niagen Bioscience closed at its highest level of the year, 1.1% above where the year started.
+0.3% · S&P 500 +0.1%
EPS of $0.03 beat the $0.01 estimate on $33.8M revenue (est. $31.5M); FY revenue guidance of $139.0M–$145.3M against the $153.3M consensus.
Story events cover the past 12 months · Times ET
+3.2% · S&P 500 −0.6%
EPS of $0.07 beat the $0.06 estimate on $31.5M revenue (est. $30.7M); FY revenue guidance of $139.0M–$145.3M against the $145.9M consensus.
−15.7% · S&P 500 −0.3%
EPS of $0.01 missed the $0.02 estimate on $29.8M revenue (est. $31.4M); FY revenue guidance of $139.0M–$145.3M against the $142.3M consensus.
−14.7% · S&P 500 −0.2%
Niagen Bioscience shares fell 8.2%, while the S&P 500 rose 0.2%.
−8.2% · S&P 500 +0.2%
EPS of $-0.01 beat the $-0.03 estimate on $27.2M revenue (est. $32.9M); FY revenue guidance of $145.3M–$151.6M against the $130.7M consensus.
−16.5%, the year's worst day · S&P 500 −4.4%
Where it ended: a close of $2.28 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 3, 2027 (EPS est. $-0.06, revenue est. $30.1M).
Nothing in the past 12 months.
All NAGE dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NAGE and SPY from Benzinga historical bars. Not investment advice.
